221 related articles for article (PubMed ID: 8787889)
1. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.
Paradis D; Vallée F; Allard S; Bisson C; Daviau N; Drapeau C; Auger F; LeBel M
Antimicrob Agents Chemother; 1992 Oct; 36(10):2085-92. PubMed ID: 1444289
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics and serum bactericidal activities of SCE-2787 and ceftazidime.
Paulfeuerborn W; Müller HJ; Borner K; Koeppe P; Lode H
Antimicrob Agents Chemother; 1993 Sep; 37(9):1835-41. PubMed ID: 8239592
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):85-8. PubMed ID: 1864280
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
Tegeder I; Bremer F; Oelkers R; Schobel H; Schüttler J; Brune K; Geisslinger G
Antimicrob Agents Chemother; 1997 Dec; 41(12):2640-5. PubMed ID: 9420033
[TBL] [Abstract][Full Text] [Related]
6. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients.
Kuo BI; Fung CP; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
9. Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.
Garau J; Blanquer J; Cobo L; Corcia S; Daguerre M; de Latorre FJ; León C; Del Nogal F; Net A; Rello J
Eur J Clin Microbiol Infect Dis; 1997 Nov; 16(11):789-96. PubMed ID: 9447899
[TBL] [Abstract][Full Text] [Related]
10. Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.
Brismar B; Malmborg AS; Tunevall G; Lindgren V; Bergman L; Mentzing LO; Nyström PO; Anséhn S; Bäckstrand B; Skau T
J Antimicrob Chemother; 1995 Jan; 35(1):139-48. PubMed ID: 7768761
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
Novelli A; Adembri C; Livi P; Fallani S; Mazzei T; De Gaudio AR
Clin Pharmacokinet; 2005; 44(5):539-49. PubMed ID: 15871639
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose pharmacokinetics of imipenem-cilastatin.
Drusano GL; Standiford HC; Bustamante C; Forrest A; Rivera G; Leslie J; Tatem B; Delaportas D; MacGregor RR; Schimpff SC
Antimicrob Agents Chemother; 1984 Nov; 26(5):715-21. PubMed ID: 6595963
[TBL] [Abstract][Full Text] [Related]
13. Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers.
Standiford HC; Drusano GL; Bustamante CI; Rivera G; Forrest A; Tatem B; Leslie J; Moody M
Antimicrob Agents Chemother; 1986 Mar; 29(3):412-7. PubMed ID: 3459390
[TBL] [Abstract][Full Text] [Related]
14. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
15. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
Keller E; Fecht H; Böhler J; Schollmeyer P
Nephrol Dial Transplant; 1989; 4(7):640-5. PubMed ID: 2510062
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Kotapati S; Kuti JL; Nicolau DP
Surg Infect (Larchmt); 2005; 6(3):297-304. PubMed ID: 16201939
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis.
Bergan T; Michalsen H; Malmborg AS; Pedersen SS; Pressler T; Storrøsten OT; Strandvik B
Chemotherapy; 1993; 39(6):369-73. PubMed ID: 8222862
[TBL] [Abstract][Full Text] [Related]
18. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group.
Colardyn F; Faulkner KL
J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.
Burman LA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
J Antimicrob Chemother; 1991 Feb; 27(2):219-24. PubMed ID: 2055812
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
Chan CY; Lai KN; Lam AW; Li PK; Chung WW; French GL
J Antimicrob Chemother; 1991 Feb; 27(2):225-32. PubMed ID: 2055813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
